SuiShot APM-7
P. multocida and A. pleuropneumoniae combined inactivated vaccine
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Brand name
- SuiShot
- Payment Terms
- L/C,T/T
- Production method
- Available,OEM
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- animal vaccine, apm-7, suishot, swine vaccine
- Category
- Veterinary Medicine
ChoongAng Vaccine Laboratories Co., Ltd.(CAVAC)
South Korea
- Verified Certificate
-
16
| Product name | SuiShot APM-7 | Certification | - |
|---|---|---|---|
| Category | Veterinary Medicine | Ingredients | Actinobacillus pleuropneumoniae serotype 2,Actinobacillus pleuropneumoniae serotype 2 toxoid,Actinobacillus pleuropneumoniae serotype 5,Actinobacillus pleuropneumoniae serotype 5 toxoid,Formalin,Immulant-α,Pasteurella multocida type A,Pasteurella multocida type D |
| Keyword | animal vaccine , apm-7 , suishot , swine vaccine | Unit Size | - |
| Brand name | SuiShot | Unit Weigh | - |
| origin | South Korea | Stock | 0 |
| Supply type | Available,OEM | HS code | 300230 |
Product Information
Toxoid vaccine with no side effects
SuiShot® APM-7
Indication
An aid in the control and prevention of porcine pleuropneumonia and pasteurellosis in pigs.
Composition and quantity (per dose)
Pasteurella multocida type A..............................................4,000,000,000 CFU
Pasteurella multocida type D..............................................4,000,000,000 CFU
Actinobacillus pleuropneumoniae serotype 2.....................2,000,000,000 CFU
Actinobacillus pleuropneumoniae serotype 5.....................2,000,000,000 CFU
Actinobacillus pleuropneumoniae serotype 2 toxoid..........20㎍
Actinobacillus pleuropneumoniae serotype 5 toxoid..........20㎍
Immulant-α..........................................................................25%
Formalin..............................................................................0.2%
Features
Protects all the serotype of actinobacillus pleuropneumoniae by neutralizing three
toxins (APX Ⅰ,Ⅱ,Ⅲ) of actinobacillus pleuropneumoniae.
The most common serotypes(type 2, 5) are included.
Prevents swine pleuropneumonia , pasteurellosis and atrophic rhinitis at once.
Formation of the vaccine immunity without the influence of antibiotic.
Nano particle adjuvant stimulates both cell-mediated immunity and humoral immunity.
Administration and dosage
For piglets, administer 2.0㎖ intramuscularly twice at 5~7 weeks of age
and 2 weeks post 1st vaccination.
Packaging unit
10 doses/bottle
25 doses/bottle
- Product Info Attached File
B2B Trade
| Price (FOB) | Negotiable | transportation | Air Transportation,Negotiation Other,Ocean Shipping |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | L/C,T/T | Shipping time | Negotiable |
- President
- Injoong Yoon
- Address
- 1476-37 Yuseong-daero, Yuseong-gu, Daejeon, Korea
- Product Category
- Veterinary Medicine
- Year Established
- 1968
- No. of Total Employees
- 101-500
- Company introduction
-
As an innovative animal vaccine company, CAVAC’s long journey with continuing efforts
CAVAC leads the way in animal health
CAVAC is a powerful leader in the field of animal biological products. We provide a wide range of groundbreaking pharmaceutical products that promote animal health and welfare, as well as improving the quality of life of people in Korea.
CAVAC’s long history and continued efforts
Since it was founded in 1968, CAVAC has grown to become renowned in Korea as a developer and manufacturer of animal vaccines. With over 80 animal vaccine products, the company is a key player in the Korean and global markets. We have achieved multiple vendor audits conducted by multinational companies and government audits. CAVAC is also committed to finding better solutions for pharmaceutical, biological and diagnostic products, and strives to be a pioneering partner offering a wide range of services.
Global bio leader in the advanced animal vaccine industry
As an animal vaccine company, CAVAC has experienced accelerated growth. As well as enhancing the development of new products and technologies, we have maximized our investments to protect against challenges and competition from various global companies. CAVAC is strategically located in the Daedeok Innopolis, also known as the Silicon Valley of Korea, and has teamed up with a number of prominent research institutions. CAVAC is now expanding onto the global market and is striving to become one of the top 10 global partners in animal health.
- Main Markets
-
Bangladesh
Cambodia
Indonesia
Myanmar
Nepal
Pakistan
Philippines
Thailand
Viet Nam
- Factory Information
-
(주)중앙백신연구소,
주식회사 중앙백신연구소
- Main Product
Related Products
Ventilator machine(PA-500) CE ISO approved
Ventilator machine(PA-700BII) China supplier
Valnemulin Hydrochloride Premix 10%
URIVET10
TRILOSIN Powder / Tylosin Tartrate
